Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858920 · ClinicalTrials.gov registry record
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
A clinical trial of NASH - Nonalcoholic Steatohepatitis and Steatosis of Liver, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 340
- Enrollment target
- 1
- Study location
NCT03858920: Completed study of NASH - Nonalcoholic Steatohepatitis and Steatosis of Liver, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03858920 is a study of NASH - Nonalcoholic Steatohepatitis and Steatosis of Liver that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 340 participants, above the 250-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03858920, a study of NASH - Nonalcoholic Steatohepatitis and Steatosis of Liver, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 340 participants
- Enrollment target
- 1
- Study location
Study Summary
This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.
Primary Outcome
assesses liver fat using a patented technique called Vibration-Controlled Transient Elastography range from 0 -400 CAP with the higher number indicating great quantity of fat in the Liver CAP 240-270 S1 Mild Steatosis CAP 270-300 S2 Moderate Steatosis CAP \>300 S3 Severe Steatosis
Conditions Studied
Interventions
- DEVICE Fibroscan of Liver
- PROCEDURE Low-dose non-contrast CT
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2021-06-11 |
What the finished NCT03858920 record still lists
NCT03858920 is an observational study that tracks outcomes without assigning an intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, above the 250-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (36% higher).
The record links to 2 conditions, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Fibroscan of Liver is the first listed.
NCT03858920 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03858920 about?
NCT03858920 is a clinical study titled "The Liver in the World Trade Center Health Program General Responder Cohort and Controls". This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.
What is the current status of trial NCT03858920?
This trial is currently completed. The enrollment target is 340 participants. The study started on 2018-05-08. Estimated completion is 2021-06-11.
What conditions does trial NCT03858920 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis, Steatosis of Liver.
What interventions are being tested in trial NCT03858920?
The interventions under investigation include: Fibroscan of Liver (DEVICE), Low-dose non-contrast CT (PROCEDURE).
Who is sponsoring clinical trial NCT03858920?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03858920 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03858920's enrollment target sits among peer trials
340 7th of 28 higher than 22 of 28 other NASH - Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NASH - Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RECRUITING · Phase 3
-
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI